Department of Cardiovascular Sciences, University of Leicester, Leicester, UK.
John Walls Renal Unit, University Hospitals of Leicester NHS Trust, Leicester, UK.
BMJ Open. 2022 Mar 25;12(3):e058368. doi: 10.1136/bmjopen-2021-058368.
Fewer trials are conducted in nephrology than any other specialty, often failing to recruit to target, resulting in unclear evidence affecting translation to clinical practice. This mixed-methods study aims to provide guidance for designing and reporting future randomised controlled trials (RCTs) in the haemodialysis population.
A scoping review was conducted. Five databases (MEDLINE, Cumulative Index to Nursing and Allied Health Literature, Embase, Cochrane Central Register of Controlled Trials and ClinicalTrials.gov) were searched for RCTs published between 2013 and 2019 involving prevalent adult haemodialysis patients. Reporting of sample size, recruitment, retention and statistical significance of primary outcome were assessed. Face-to-face semistructured interviews were conducted with individuals from a single centre during dialysis sessions. Interviews were analysed thematically.
Of 786 RCTs identified, 636 (80.9%) were parallel-group, 139 (17.7%) were crossover and 11 (1.4%) were cluster (including one stepped-wedge) design. Sample size justification was reported in 73.1%, 53.8% and 45.5% of parallel-group, crossover and cluster trials, respectively.Target recruitment was achieved by 45.5% of cluster, 53.8% of crossover and 57.7% of parallel-group trials with patient retention at 75.6%, 83.1% and 87.8%, respectively. Primary outcome reached statistical significance in 81.8% of cluster trials, 69.2% of parallel-group and 38.5% of crossover trials.Themes identified from individual interviews: perceptions of the convenience of trial participation; group allocation; perceptions of the benefits and adverse effects of taking part in clinical trials.
The recruitment and reporting of RCTs involving people on haemodialysis could be improved. Involvement of all stakeholders and especially participants in the trial design process may address issues around participant burden and ultimately improve the evidence base for clinical practice.
肾病学领域开展的试验比其他任何专业都少,常常无法达到目标招募人数,导致证据不明确,影响到向临床实践的转化。这项混合方法研究旨在为设计和报告未来血液透析人群中的随机对照试验(RCT)提供指导。
进行了范围综述。在 2013 年至 2019 年期间,检索了五个数据库(MEDLINE、护理学及相关健康学科累积索引、Embase、Cochrane 对照试验中心注册库和 ClinicalTrials.gov),以查找涉及成年现患血液透析患者的 RCT。评估了样本量、招募、保留和主要结局的统计学意义的报告情况。在透析期间对来自单一中心的个人进行了面对面半结构化访谈。对访谈进行了主题分析。
在确定的 786 项 RCT 中,636 项(80.9%)为平行组设计,139 项(17.7%)为交叉设计,11 项(1.4%)为群组(包括一项逐步楔形)设计。分别有 73.1%、53.8%和 45.5%的平行组、交叉组和群组试验报告了样本量的论证。群组、交叉和平行组试验的目标招募率分别为 45.5%、53.8%和 57.7%,患者保留率分别为 75.6%、83.1%和 87.8%。81.8%的群组试验、69.2%的平行组试验和 38.5%的交叉试验的主要结局达到了统计学意义。从个人访谈中确定的主题:对试验参与便利性的看法;分组;参与临床试验的益处和不良反应的看法。
参与血液透析的人群的 RCT 的招募和报告可以得到改善。让所有利益相关者,特别是参与者参与试验设计过程,可能会解决参与者负担问题,并最终改善临床实践的证据基础。